A TREM1 variant alters the accumulation of alzheimer-related amyloid pathology

Annals of Neurology

Volumn 77, Issue 3, 2015, Pages 469-477

  Replogle, Joseph M ^a,b,c,d   Chan, Gail ^a,b,c,d   White, Charles C ^a,b,c   Raj, Towfique ^a,b,c,d   Winn, Phoebe A ^a,b,c   Evans, Denis A ^e   Sperling, Reisa A ^a,d   Chibnik, Lori B ^a,b,c,d   Bradshaw, Elizabeth M ^a,b,c,d   Schneider, Julie A ^e   Bennett, David A ^e   De Jager, Philip L ^a,b,c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; MEMBRANE RECEPTOR; TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; UNCLASSIFIED DRUG; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; TREM1 PROTEIN, HUMAN;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; BONE MARROW CELL; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; DENSITY; DISEASE ASSOCIATION; ENDOPHENOTYPE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE LOCUS; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MONOCYTE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENILE PLAQUE; AMYLOID PLAQUE; BRAIN CORTEX; GENETICS; METABOLISM; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; CEREBRAL CORTEX; COGNITION DISORDERS; COHORT STUDIES; ENDOPHENOTYPES; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; RECEPTORS, IMMUNOLOGIC;

EID: 84923666918     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24337     Document Type: Article

References (47)

1. Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer's disease. N Engl J Med 2013; 368: 117-127.
2. Jonsson T, Stefansson H, Steinberg S, et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 2013; 368: 107-116.
3. Benitez BA, Cooper B, Pastor P, et al. TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiol Aging 2013; 34: 1711e15-1711e17.
4. Ruiz A, Dols-Icardo O, Bullido MJ, et al. Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 2014; 35: 444.e1-444.e4.
5. Jin SC, Benitez BA, Karch CM, et al. Coding variants in TREM2 increase risk for Alzheimer's disease. Hum Mol Genet 2014; 23: 5838-5846.
6. Turnbull IR, Gilfillan S, Cella M, et al. Cutting edge: TREM-2 attenuates macrophage activation. J Immunol 2006; 177: 3520-3524.
7. Hamerman JA, Jarjoura JR, Humphrey MB, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)22 and DAP12. J Immunol 2006; 177: 2051-2055.
8. Jiang T, Yu JT, Zhu XC, Tan L. TREM2 in Alzheimer's disease. Mol Neurobiol 2013; 48: 180-185.
9. Frank S, Burbach GJ, Bonin M, et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 2008; 56: 1438-1447.
10. Bradshaw EM, Chibnik LB, Keenan BT, et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci 2013; 16: 848-850.
11. Griciuc A, Serrano-Pozo A, Parrado AR, et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 2013; 78: 631-643.
12. Malik M, Simpson JF, Parikh I, et al. CD33 Alzheimer's riskaltering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci 2013; 33: 13320-13325.
13. Raj T, Ryan KJ, Replogle JM, et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility. Hum Mol Genet 2014; 23: 2729-2736.
14. Allcock RJ, Barrow AD, Forbes S, et al. The human TREM gene cluster at 6p21.1 encodes both activating and inhibitory single IgV domain receptors and includes NKp44. Eur J Immunol 2003; 33: 567-577.
15. Colonna M. TREMs in the immune system and beyond. Nat Rev Immunol 2003; 3: 445-453.
16. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol 2009; 21: 38-46.
17. Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 2013; 153: 707-720.
18. Cruchaga C, Kauwe JS, Harari O, et al. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013; 78: 256-268.
19. Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 2013; 45: 1452-1458.
20. Benitez BA, Jin SC, Guerreiro R, et al. Missense variant in TREML2 protects against Alzheimer's disease. Neurobiol Aging 2014; 35: 1510.e19-1510.e26.
21. Chibnik LB, Shulman JM, Leurgans SE, et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 2011; 69: 560-569.
22. Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. Curr Alzheimer Res 2012; 9: 628-645.
23. Bennett DA, Schneider JA, Buchman AS, et al. Overview and findings from the Rush Memory and Aging Project. Curr Alzheimer Res 2012; 9: 646-663.
24. Bennett DA, Schneider JA, Buchman AS, et al. The Rush Memory and Aging Project: study design and baseline characteristics of the study cohort. Neuroepidemiology 2005; 25: 163-175.
25. Bienias JL, Beckett LA, Bennett DA, et al. Design of the Chicago Health and Aging Project (CHAP). J Alzheimers Dis 2003; 5: 349-355.
26. Keenan BT, Shulman JM, Chibnik LB, et al. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 2012; 21: 2377-2388.
27. Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. Neurology 2002; 59: 198-205.
28. Bennett DA, Schneider JA, Arvanitakis Z, et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66: 1837-1844.
29. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology 2005; 64: 834-841.
30. Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. Neurology 2004; 62: 1148-1155.
31. Barnes LL, Schneider JA, Boyle PA, et al. Memory complaints are related to Alzheimer disease pathology in older persons. Neurology 2006; 67: 1581-1585.
32. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-1124.
33. Arvanitakis Z, Leurgans SE, Wang Z, et al. Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 2011; 69: 320-327.
34. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
35. Buchman AS, Yu L, Boyle PA, et al. Microvascular brain pathology and late-life motor impairment. Neurology 2013; 80: 712-718.
36. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
37. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
38. Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods 2010; 15: 309-334.
39. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014; 344: 519-523.
40. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007; 8: 118-127.
41. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, et al. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 2006; 27: 1644-1657.
42. Bennett DA, Schneider JA, Wilson RS, et al. Education modifies the association of amyloid but not tangles with cognitive function. Neurology 2005; 65: 953-955.
43. Su L, Liu C, Li C, et al. Dynamic changes in serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) and its gene polymorphisms are associated with sepsis prognosis. Inflammation 2012; 35: 1833-1843.
44. Weigelt K, Carvalho LA, Drexhage RC, et al. TREM-1 and DAP12 expression in monocytes of patients with severe psychiatric disorders. EGR3, ATF3 and PU.1 as important transcription factors. Brain Behav Immun 2011; 25: 1162-1169.
45. Garwood CJ, Cooper JD, Hanger DP, Noble W. Anti-inflammatory impact of minocycline in a mouse model of tauopathy. Front Psychiatry 2010; 1: 136.
46. Melchior B, Garcia AE, Hsiung BK, et al. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease. ASN Neuro 2010; 2:e00037.
47. Weber B, Schuster S, Zysset D, et al. TREM-1 deficiency can attenuate disease severity without affecting pathogen clearance. PLoS Pathog 2014; 10:e1003900.